Stock CYCC CYCLACEL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
2 USD -19.68% Intraday chart for Cyclacel Pharmaceuticals, Inc. +32.45% -25.09%
May. 02 Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding CI
Apr. 30 Top Midday Gainers MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Brookline Capital Downgrades Cyclacel Pharmaceuticals to Hold From Buy
MT
Oppenheimer Adjusts Cyclacel Pharmaceuticals Price Target to $8 From $10, Maintains Outperform Rating
MT
Oppenheimer Adjusts Cyclacel Pharmaceuticals Price Target to $10 From $17, Maintains Outperform Rating
MT
Roth Capital Adjusts Cyclacel Pharmaceuticals Price Target to $16 From $24, Maintains Buy Rating
MT
CYCLACEL PHARMACEUTICALS : Oppenheimer Initiates Cyclacel Pharmaceuticals at Outperform Rating With $17 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYCC Stock
  4. News Cyclacel Pharmaceuticals, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW